Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2012 by Yonsei University.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Moon Young Kim, Yonsei University Identifier:
First received: November 10, 2011
Last updated: December 7, 2012
Last verified: December 2012

Background & Aim: Bone marrow derived mesenchymal stem cells (BM-MSCs) have capacity to differentiate into hepatocytes and anti-fibrotic effect in the experimental model. No study was done in humans with alcoholic liver cirrhosis. The researchers investigated the anti-fibrotic effect of BM-MSCs in alcoholic cirrhosis as Phase II clinical study.

Methods: Eleven alcoholic cirrhosis patients (M:F = 10:1) with Child-Pugh's class B and maintenance of alcohol abstinence at least 2 months were enrolled. At baseline, all patients received liver biopsy, hepatic venous pressure gradient (HVPG) measurement and serologic tests. BM-MSCs were isolated from each patient's BM and amplified for one month and injected two times at 4, 8week through Rt. hepatic artery. 5x106cells/mL of BM-MSCs were injected in each session. Follow up biopsy, HVPG and relative expression of tissue transforming growth factor-1 (TGF-β1), α smooth muscle actin (α-SMA) and collagen-1 by real time RT PCR were measured after 12weeks from 2nd BM-MSC injection. The primary outcome was improvement in patients' histology Aim :

The researchers aimed to evaluate safety and effectiveness of new therapy with bone marrow derived autologous mesenchymal stem cell for hepatic failure caused by alcoholic liver cirrhosis.

Condition Intervention Phase
Alcoholic Liver Cirrhosis
Biological: mesenchymal stem cell injection
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Evaluation of Effectiveness and Safety for New Therapy With Bone Marrow Derived Autologous Mesenchymal Stem Cell for Hepatic Failure Caused by Alcoholic Liver Cirrhosis

Resource links provided by NLM:

Further study details as provided by Yonsei University:

Primary Outcome Measures:
  • The improvement of Liver Histologic grade [ Time Frame: 6 months later ]
    according to Metavir and Laennec fibrosis scoring system

Secondary Outcome Measures:
  • The evaluation of hepatic dendritic cells activity by immunohistochemistry [ Time Frame: baseline and 6 months later ]
  • Liver fibrosis quantitative analysis using Hydroxyproline contents in liver tissue [ Time Frame: baseline and 6 months later ]
    Hydroxyproline is a essential component of collange fiber

  • Real-Time Polymerase Chain Reaction for relative mRNA expression of TGF-beta, collagen, procollagen, MMP2 or 9 [ Time Frame: baseline and 6 months later ]
  • Hepatic venous pressure gradient(HVPG) [ Time Frame: baseline and 6 months later ]
    HVPG is a gold standard to measure the portal hypertension.

  • Hepatic vein arrival time using microbubble contrast enhanced ultrasonography [ Time Frame: baseline and 6 months later ]
    Hepatic vein arrival time is related with portal hypertension and intrahepatic inflammation, neoangiogenesis and shunts formation secondary to hepatic fibrosis.

  • Liver stiffness measurement with transient elastography [ Time Frame: baseline and 6 months later ]
    Recently, hepatic fibrosis can be estimated non-invasively using transient elastography (Fibroscan, commercial name) and it can be additive data in estimation of therapeutic response.

  • Child-Pugh score [ Time Frame: baseline and 6 months later ]
  • MELD score [ Time Frame: baseline and 6 months later ]

Estimated Enrollment: 12
Study Start Date: September 2009
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MSC injection
This study is designed as single interventional arm without comparative arm. MSC injection means hepatic artery catheterizations and mesenchymal stem cell injection through catheter.
Biological: mesenchymal stem cell injection
Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.

Detailed Description:
Autologous BM-MSCs therapy in alcoholic cirrhosis induces improvement of hepatic fibrosis in histological and quantitative measurements.

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Alcoholic liver cirrhosis(child Pugh class B or C, ≥ 7 scores),confirmed by clinically or biopsy.
  2. Stop drinking over past 6months.
  3. Patients agree with informed consent Patients must satisfy all inclusion criteria.

Exclusion Criteria:

  1. Patients who did not satisfy inclusion criteria
  2. Hepatocellular carcinoma
  3. Pregnancy or breast feeding
  4. Infective disease(HIV, HBV, HCV..)
  5. Other incurable malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01741090

Contact: Soon Koo Baik, M.D., PhD 82-33-741-1229
Contact: Moon Young Kim, M.D., PhD 82-33-741-1225

Korea, Republic of
Yonsei University Wonju College of Medicine Wonju Christian Hospital Recruiting
Wonju, Kangwon-do, Korea, Republic of, 220-701
Contact: Soon Koo Baik, M.D    82-33-741-1229   
Contact: Moon Young Kim, M.D    82-33-741-1225   
Principal Investigator: Soon Koo Baik, M.D         
Sub-Investigator: Moon Young Kim, M.D         
Sponsors and Collaborators
Yonsei University
Principal Investigator: Soon Koo Baik, M.D Yonsei University Wonju College of Medicine Department of Internal Medicine Devision of Gastroenterology and Hepatology
  More Information


Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Moon Young Kim, Associate Professor, Yonsei University Identifier: NCT01741090     History of Changes
Other Study ID Numbers: CR109021
Study First Received: November 10, 2011
Last Updated: December 7, 2012

Keywords provided by Yonsei University:
Autologous Mesenchymal stem cell
alcoholic liver cirrhosis

Additional relevant MeSH terms:
Liver Cirrhosis
Liver Cirrhosis, Alcoholic
Pathologic Processes
Liver Diseases
Digestive System Diseases
Liver Diseases, Alcoholic
Alcohol-Induced Disorders
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders processed this record on April 26, 2017